Neramexane modified release matrix tablet

Details for Australian Patent Application No. 2006319411 (hide)

Owner Merz Pharma GmbH & Co. KgaA

Inventors Hauptmeier, Bernhard; Becker, Andreas

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2006319411

PCT Pub. Number WO2007/062815

Priority 60/740,975 30.11.05 US

Filing date 29 November 2006

Wipo publication date 7 June 2007

Acceptance publication date 16 September 2010

International Classifications

A61K 31/13 (2006.01) - Amines, e.g. amantadine

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 9/28 (2006.01) Medicinal preparations characterised by special physical form - Dragees

Event Publications

22 May 2008 PCT application entered the National Phase

  PCT publication WO2007/062815 Priority application(s): WO2007/062815

16 September 2010 Application Accepted

  Published as AU-B-2006319411

21 October 2010 Corrigenda

  Applications Accepted - Name Index Under the name Merz Pharma GmbH & Co. KgaA, Application No. 2006319411, under INID (71) correct the applicant name to Merz Pharma GmbH & Co. KGaA

20 January 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006319415-Multimeric complexes of antigens and an adjuvant

2006319401-3-(substituted amino)-pyrazolo[3,4-d]pyrimidines as EphB and VEGFR2 kinase inhibitors